Reviewing Corcept Therapeutics (CORT) and Its Peers

Corcept Therapeutics (NASDAQ:CORT) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Corcept Therapeutics to related companies based on the strength of its profitability, valuation, analyst recommendations, risk, dividends, earnings and institutional ownership.

Profitability

This table compares Corcept Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	16.53%	24.00%	18.82%
Corcept Therapeutics Competitors	-2,381.20%	-218.66%	-15.76%

Valuation and Earnings

This table compares Corcept Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Corcept Therapeutics	$761.41 million	$99.65 million	188.62
Corcept Therapeutics Competitors	$3.55 billion	$3.18 billion	548.15

Corcept Therapeutics’ competitors have higher revenue and earnings than Corcept Therapeutics. Corcept Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Corcept Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Corcept Therapeutics’ competitors have a beta of -3.76, meaning that their average stock price is 476% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Corcept Therapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1	2	5	0	2.50
Corcept Therapeutics Competitors	7770	13861	25735	1032	2.41

Corcept Therapeutics presently has a consensus price target of $139.50, indicating a potential upside of 76.09%. As a group, “Pharmaceuticals” companies have a potential upside of 22.68%. Given Corcept Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Corcept Therapeutics is more favorable than its competitors.

Institutional and Insider Ownership

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Corcept Therapeutics beats its competitors on 9 of the 13 factors compared.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.